No abstract

Background and Objectives: Seroprevalence estimation of COVID-19 is quite necessary for controlling the transmission of SARS-CoV-2 infection. Seroprevalence rate in recovered COVID-19 patients help us to identify individual with anti-SARS-CoV-2 antibodies and its protective nature. The objective of present study was to evaluate seroprevalence of SARS-CoV-2 among potential convalescent plasma donors and analysis of their deferral reasons. Materials and Methods: A total 400 potential convalescent plasma donors were enrolled over five-month period for this prospective study. Inclusion criteria were lab confirmed COVID-19 recovered patients and 14 days of symptoms free period. All prospective plasmapheresis donors were tested for IgG SARS-CoV-2 antibody through chemiluminescent microparticle immunoassay, CBC, serum protein, blood grouping along with other required test for normal blood donation as per Drugs & Cosmetics Act. After pre donation testing and medical examination if donor was found to be ineligible for plasmapheresis was deferred. Seroprevalence rate was calculated by positive IgG antibody test results among the potential plasma donors. Results: Seroprevalence rate was 87% for IgG SARS-CoV-2 antibodies in prospective convalescent plasma donors (recovered COVID-19 patients). There was no significant difference in seroprevalence rate between different sub-groups with respect to gender, age, blood groups, Rh factor, mode of treatment, day of Ab testing and repeat plasma donation. Most common reason for their deferral was absent IgG SARS-CoV-2 antibodies (13%) followed by absenteeism of eligible screen donors (6.7%), low Hb (1.7%) and poor veins for plasmapheresis (1.7%). Till five-month study period none of the plasmapheresis develop symptoms of reinfection with COVID-19. Conclusion: 13% recovered patients did not develop IgG antibodies after SARS-CoV-2 infection. SARS-CoV-2 IgG antibodies persist for quite some time and are protective against reinfection. More long-term serology studies are needed to understand better antibody response kinetics and duration of persistence of IgG antibodies.

No abstract

No abstract

Blood transfusion plays a vital role in Obstetrics and Gynaecology and appropriate transfusion practices can prove as a boon to patient with minimal adverse reactions. Several diseases in obstetrics like, Obstetric haemorrhage, especially postpartum haemorrhage and antepartum haemorrhage, severe anaemia, ectopic pregnancy, molar pregnancy requires immediate transfusion of blood to reduce maternal mortality. In gynaecological practice, certain conditions like broids, cervical cancer, endometrium cancer, ovarian cancer, hysterectomy requires transfusion of blood mostly to recover operative loss of blood. Written informed consent and pre-transfusion testing is very important before start of transfusion. For this purpose, role of transfusion medicine specialist is equally important e.g. from the selecting of appropriate blood and blood components to the pre-transfusion testing and antibody screening of patient's sample. Though, blood transfusion is a lifesaving process in critical conditions but it is not without side effects and risks. Therefore, some strategies have been designed to avoid blood transfusion. In conclusion, we can say that before every transfusion risk benet ratio must be kept in mind and appropriate transfusion practices should be adopted for every blood transfusion.